Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | ELANE | P08246 | 1/20 | 0.56 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11084513 | 0.82 | FFAR1 (0.61) | FFAR1ALDH1A1CTSBELANEDUSP3 | |
| SCHEMBL16374497 | 0.82 | FFAR1 (0.61) | FFAR1ALDH1A1CTSBELANEDUSP3 | |
| SCHEMBL3892694 | 0.79 | FFAR1 (0.57) | FFAR1ALDH1A1CTSBELANEDUSP3 | |
| SCHEMBL991241 | 0.78 | FFAR1 (0.68) | FFAR1ALDH1A1CTSBELANEDUSP3 | |
| SCHEMBL74365 | 0.78 | FFAR1 (1.00) | FFAR1ALDH1A1CTSBELANEDUSP3 | |
| Ethylene Glycol SCHEMBL9808276 | 0.78 | FFAR1 (0.61) | FFAR1ALDH1A1CTSBELANEDUSP3 | |
| SCHEMBL3105393 | 0.77 | MAPT (0.51) | FFAR1ALDH1A1GAAHSD17B10CYP2C19 | |
| SCHEMBL8676125 | 0.77 | FFAR1 (0.65) | FFAR1ALDH1A1CTSBELANEDUSP3 | |
| SCHEMBL883102 | 0.77 | FFAR1 (0.65) | FFAR1ALDH1A1CTSBELANEDUSP3 | |
| SCHEMBL632287 | 0.77 | SMN1; SMN2 (0.68) | FFAR1ALDH1A1CTSBELANEDUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-7803793-B2 | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-28 | — | — | US | disclosed |
| US-20090246700-A1 | PLATE-MAKING METHOD OF LITHOGRAPHIC PRINTING PLATE PRECURSOR | FUJIFILM CORPORATION (JP) | 2009-10-01 | — | — | US | disclosed |
| CN-101547908-A | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-30 | — | — | CN | disclosed |
| EP-2089365-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-08-19 | — | — | EP | disclosed |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008045668-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-17 | — | — | WO | disclosed |
| EP-1812386-A1 | PROCESS FOR ALKYL ARYL SULFIDE DERIVATIVES AND NEW SULFIDE COMPOUNDS | Kang, Heonjoong (KR) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006043797-A1 | PROCESS FOR ALKYL ARYL SULFIDE DERIVATIVES AND NEW SULFIDE COMPOUNDS | KANG HEONJOONG (KR) | 2006-04-27 | — | — | WO | disclosed |
| EP-0100158-A2 | (3-pyridinyl)heteroalkarylalkanols, alkanoic acids and esters | THE UPJOHN COMPANY (US) | 1984-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | FFAR1 4171/4885ALDH1A1 530/4885CTSB 63/4885 |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | FFAR1 4171/4885ALDH1A1 530/4885CTSB 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.